Novel Approach for Evaluating and Treating Advanced Breast Cancer Patients Whose Tumors Overexpress HER-2/neu

Abstract

The goal of this research is to develop stable radioimmunoconjugates (RICs) of an anti-HER 2/neu antibodies (MoAbs) for imaging and therapy in an animal model bearing human breast tumors. Pharmacy-grade Herceptin and an anti-HER2/neu antibody were conjugated with a DTPA linker. InCl(3)111 and YCl(3)90 were labeled to MoAb-CHX-A"-DTPA according to the procedure of Clarke et al. (Cancer Res 60: 4804, 2000). Binding capacity of RICs was tested with human cancer cell lines MCF-7, HCC-1954, BT-474 and SKBR-3.

Open PDF

Document Details

Document Type
Technical Report
Publication Date
May 01, 2003
Accession Number
ADA418094

Entities

People

  • Michael J. Blend

Organizations

  • University of Illinois at Chicago

Tags

DTIC Thesaurus Topics

  • Azo Compounds
  • Breast Cancer
  • Cell Line
  • Cells
  • Chemical Synthesis
  • Chemistry
  • Diseases And Disorders
  • Health Services
  • Medical Personnel
  • Neoplasms
  • Proteins
  • Sodium Compounds
  • Tumor Cell Line

Fields of Study

  • Biology
  • Medicine

Readers

  • Oncology (Cancer Research).